BI-1403-0002
A phase Ia/Ib, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors Protocol:...
BLU-667
CD8 PET imaging studie (GENENTECH)
Een fase 1-2 immunoPET imaging studie met ZED88082A/CED88004S in patiënten voor en tijdens behandeling met 1) MPDL3280A of 2) PD-1 antilichaam met of zonder ipilimumab. Protocolnummer: Eudract nummer:...
DEBIO-0123
A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors. Protocolnummer: Debio 0123-101 EudraCT nummer: 2018-003659-39 METc nummer: 2019/631 Samenvatting...
Dragonfly DF1001-001
A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or...
GE-269-001
A phase 1a/1b, multi centre, open-label, dose-escalation and dose-expansion study in patients with solid tumour malignancies to evaluate GEH200520 Injection / GEH200521 (18F) Injection safety and tolerability, positron...
GO41596
A phase Ia/Ib, open-label, multicenter, global, dose-escalation study to evaluate the safety and pharmacokinetics of XmAb24306 as a single agent and in combination with atezolizumab in patients with...
INCB81776-101
A Phase 1a/1b Study exploring the safety and tolerability of INCB081776 +/- retifanlimab in participants with advanced malignancies Protocol: INCB 81776-101 EudraCT Number: 2020-004867-26 Een Fase 1a/1b, open label...
LAG-3
ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemipliamb with or without platinum-based chemotherapy. Samenvatting 89Zr-DFO-REGN3767 is een experimentele PET...
PD-L1 Imaging
PD-L1 treatment
Potentia
A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, harmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced...
Potentia CBT307-1-RL (Imaging)
A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA-Tumour Lesions Eudractnummer: 2021-006256-13 CB307 is een trispecifieke Humabody® gericht op CD137; PSMA; en humaan serumalbumine...
Regeneron 5054
A First-In-Human study of 89ZR-DFO-REGN5054 (anti-CD8) Positron Emission Tomograpghy in patients with solid malignancies treated with Cemiplimab. Eudractnummer: 2019-001604-38 Samenvatting De primaire doelstelling van het onderzoek is het...
Servier CL-98012-002
An open label, multicentre, positron emission tomography (PET) imaging study using Zirconium-89 to investigate the biodistribution and tumor uptake of a PD-L1x4-1BB bispecific antibody (SO95012) in patients with...